{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:53:25Z","timestamp":1788951205692,"version":"build-2803163510"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cardiogenic shock is a rare adverse event of 5-fluorouracil (5-FU) administration. Because of its rare entity, little is known about epidemiologic and clinical features of 5-FU-induced cardiogenic shock, and recommendations about specific treatment are missing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>We present a case of cardiogenic shock and ventricular arrhythmia due to 5-FU-induced toxic cardiomyopathy treated with vasopressor and inotropic drugs in combination with intra-aortic balloon pump. Because of persistent haemodynamic instability, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and Impella were implanted as a bridge to recovery. Systolic function recovered completely and the patient was weaned successfully.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>This case demonstrates toxic cardiomyopathy as a rare and potentially lethal cardiac adverse event of 5-FU administration. This case emphasizes the importance of mechanical support as bridging therapy to recovery of cardiac function.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytad596","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T04:30:12Z","timestamp":1702441812000},"source":"Crossref","is-referenced-by-count":4,"title":["Cardiogenic shock after 5-fluorouracil administration: a case report and literature review"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6887-8405","authenticated-orcid":false,"given":"Lowie","family":"Vanoverbeke","sequence":"first","affiliation":[{"name":"Department of Cardiology, AZ Groeninge , President Kennedylaan 4 , Kortrijk 8500, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holvoet","family":"Wouter","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AZ Groeninge , President Kennedylaan 4 , Kortrijk 8500, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u2019Heygere","family":"Fran\u00e7ois","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, AZ Groeninge , Kortrijk , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elegeert","family":"Ivan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AZ Groeninge , President Kennedylaan 4 , Kortrijk 8500, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"key":"2024030519572312900_ytad596-B1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s12012-020-09562-w","article-title":"Various manifestations of 5-fluorouracil cardiotoxicity: a multicenter case series and review of literature","volume":"20","author":"Allison","year":"2020","journal-title":"Cardiovasc Toxicol"},{"key":"2024030519572312900_ytad596-B2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000072334","article-title":"High incidence of angina pectoris in patients treated with 5-fluorouracil. A planned surveillance study with 102 patients","volume":"65","author":"Wacker","year":"2003","journal-title":"Oncology"},{"key":"2024030519572312900_ytad596-B3","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","article-title":"Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study","volume":"10","author":"de Forni","year":"1992","journal-title":"J Clin Oncol"},{"key":"2024030519572312900_ytad596-B4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.15420\/icr.2019.12","article-title":"Coronary artery vasospasm induced by 5-fluorouracil: proposed mechanisms, existing management options and future directions","volume":"14","author":"Chong","year":"2019","journal-title":"Interv Cardiol"},{"key":"2024030519572312900_ytad596-B5","doi-asserted-by":"crossref","first-page":"461","DOI":"10.5152\/akd.2010.147","article-title":"Two cases of coronary vasospasm induced by 5-fluorouracil","volume":"10","author":"Atar","year":"2010","journal-title":"Anadolu Kardiyol Derg"},{"key":"2024030519572312900_ytad596-B6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/107327480401100107","article-title":"5-Fluorouracil-induced coronary vasospasm","volume":"11","author":"Shoemaker","year":"2004","journal-title":"Cancer Control"},{"key":"2024030519572312900_ytad596-B7","doi-asserted-by":"crossref","first-page":"E111","DOI":"10.15420\/ahhj.2010.8.2.111","article-title":"Angina induced by 5-fluorouracil infusion in a patient with normal coronaries","volume":"8","author":"Tajik","year":"2010","journal-title":"Am Heart Hosp J"},{"key":"2024030519572312900_ytad596-B8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ctrv.2013.03.005","article-title":"Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors","volume":"39","author":"Polk","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"2024030519572312900_ytad596-B9","doi-asserted-by":"crossref","first-page":"5280","DOI":"10.1200\/JCO.2009.27.3953","article-title":"Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle","volume":"28","author":"Jensen","year":"2010","journal-title":"J Clin Oncol"},{"key":"2024030519572312900_ytad596-B10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ccl.2019.07.004","article-title":"Fluoropyrimidine-associated cardiotoxicity","volume":"37","author":"Kanduri","year":"2019","journal-title":"Cardiol Clin"},{"key":"2024030519572312900_ytad596-B11","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jjco\/hyh047","article-title":"Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil\/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers","volume":"34","author":"Oztop","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"2024030519572312900_ytad596-B12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"2024030519572312900_ytad596-B13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1310\/hpj5106-484","article-title":"Uridine triacetate","volume":"51","author":"Cada","year":"2016","journal-title":"Hosp Pharm"},{"key":"2024030519572312900_ytad596-B14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.30321","article-title":"Emergency use of uridine triacetate for the prevention and treatment of life threatening 5-fluorouracil and capecitabine toxicity","volume":"123","author":"Ma","year":"2017","journal-title":"Cancer"},{"key":"2024030519572312900_ytad596-B15","first-page":"1675","article-title":"Cardiac toxicity of 5-fluorouracil. Review of the literature, 5 new cases","volume":"17","author":"Clavel","year":"1988","journal-title":"Presse Med"},{"key":"2024030519572312900_ytad596-B16","doi-asserted-by":"crossref","first-page":"970979","DOI":"10.21037\/jgo.2017.09.07","article-title":"Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm","volume":"8","author":"Clasen","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"2024030519572312900_ytad596-B17","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytad596\/54418356\/ytad596.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/7\/12\/ytad596\/56844318\/ytad596.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/7\/12\/ytad596\/56844318\/ytad596.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T19:57:40Z","timestamp":1709668660000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytad596\/7471855"}},"subtitle":[],"editor":[{"given":"Diego","family":"Araiza-Garaygordobil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Maria Concetta","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Franca","family":"Morselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":17,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytad596","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,12,1]]},"article-number":"ytad596"}}